cancer-patients / English

add

(MedPage Today) -- BERLIN -- Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) in patients with BCG-naive, high-risk non-muscle-invasive…

(MedPage Today) -- BERLIN -- In a global phase III trial, the addition of durvalumab (Imfinzi) to standard chemotherapy given before and after surgery led to a statistically significant and "clinically meaningful" survival improvement in…

A new hub at Newcastle University will benefit cancer patients and researchers

A dual cannabinoid agonist drug candidate is being investigated for its potential in treating wasting syndrome in cancer patients.

Some 77% of patients saw their tumours shrink, 8% saw them completely disappear, and 69% saw partial shrinkage of their tumours.

Some 77% of patients saw their tumours shrink, 8% saw them completely disappear, and 69% saw partial shrinkage of their tumours.

Some 77% of patients saw their tumours shrink, 8% saw them completely disappear, and 69% saw partial shrinkage of their tumours.

Some 77% of patients saw their tumours shrink, 8% saw them completely disappear, and 69% saw partial shrinkage of their tumours.

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small…

Legalizing marijuana for medical or recreational purposes is “significantly associated with reduced opioid use among patients diagnosed with cancer,” according to a new federally funded study published by the American Medical Association …

An alliance of scientists at the Broad Institute and Bayer Pharmaceuticals have developed a drug candidate, sevabertinib, that could be a new treatment for a group of lung cancer patients who have few options today.

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR…

Researchers appear to have found a solution for younger patients who do not respond well enough to tamoxifen

In oncology, progress is often described in cautious terms: a few months’ extra survival, a slightly improved quality of life, a percentage-point increase in remission. These steps matter, but they also reflect an industry built around…

Google has announced a new open-source AI/ML model, ‘DeepSomatic’, which was developed in partnership with the UC Santa Cruz Genomics Institute and Children’s Mercy. DeepSomatic can accurately identify genetic variants in cancer cells to…

Researchers from The University of Texas MD Anderson Cancer Center have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer.

Breast cancer is the most common cancer among women worldwide (WHO, 2023). The Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) has now developed a new therapy in a clinical study that tailors hormone treatment for…

In cancer patients, the health of the thymus—a key part of the body's immune system—is associated with the outcomes these patients experience after immune checkpoint inhibitor treatment, according to an international study reported at ESMO…

The ultimate cause of death from cancer may not be metastatic disease, as researchers have long surmised, but an infiltration of tumors into major blood vessels that cause blood clots and multiorgan failure, a one-of-a-kind clinical study…